Summary: Centessa Pharmaceuticals has presented preclinical data on ORX142, an investigational orexin receptor 2 (OX2R) agonist, during the 27th Congress of the European Sleep Research Society. ORX142 demonstrated significant wake-promoting effects in non-human primates at very … [Read more...]
ORX750 Significantly Increased Wakefulness in Sleep-Deprived Individuals
Summary: Centessa Pharmaceuticals announced positive interim data from its ongoing phase 1 trial of ORX750, an orexin receptor 2 agonist, in acutely sleep-deprived healthy volunteers. The trial demonstrated that ORX750 significantly increased wakefulness, with the 2.5 mg dose … [Read more...]
Centessa’s ORX142 Promotes Wakefulness in Preclinical Models
Summary: Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, an orexin receptor 2 (OX2R) agonist designed to address excessive daytime sleepiness (EDS) in various neurological, neurodegenerative, and psychiatric disorders, will be … [Read more...]
ALKS 2680 Improves Wakefulness in Narcolepsy Type 2 and IH
Summary: Alkermes plc introduced favourable benefits from a phase 1b research evaluating ALKS 2680, an oral orexin 2 receptor agonist, for dealing with narcolepsy variety 2 and idiopathic hypersomnia. The analyze showed statistically sizeable enhancements in wakefulness and rest … [Read more...]